ArticleCancer research2017
Loss of FOXO1 Cooperates with TMPRSS2-ERG Overexpression to Promote Prostate Tumorigenesis and Cell Invasion.
Abstract read
In one paragraph
Article in Cancer research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed
3.4field-weighted citation impact, top 7% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 86 citations in OpenAlex.
- SPOP-mediated ZMYND8 ubiquitination and phase separation exclusion drives mTOR inhibitor resistance in kidney cancer.Nature communications · 2026Article
- Molecular insights for the tumor suppressor role of SPOP in prostate cancer.Biochimica et biophysica acta. Reviews on cancer · 2026Review
- Transcriptional and epigenetic reprogramming, lineage plasticity and therapy resistance in prostate cancer.Journal of the National Cancer Center · 2026Review
- High clonal diversity and spatial genetic admixture in early prostate cancer and surrounding normal tissue.Nature communications · 2024Article
- Calcium signalling pathways in prostate cancer initiation and progression.Nature reviews. Urology · 2023Review
- Gain-of-function mutant p53 together with ERG proto-oncogene drive prostate cancer by beta-catenin activation and pyrimidine synthesis.Nature communications · 2023Article
- A lncRNA from the FTO locus acts as a suppressor of the mMolecular cell · 2023Article
- The Role of Polo-Like Kinase 1 in Regulating the Forkhead Box Family Transcription Factors.Cells · 2023Review
- Upregulation of GALNT7 in prostate cancer modifies O-glycosylation and promotes tumour growth.Oncogene · 2023Article
- Addressing the Reciprocal Crosstalk between the AR and the PI3K/AKT/mTOR Signaling Pathways for Prostate Cancer Treatment.International journal of molecular sciences · 2023Review
- A FOXO1-dependent transcription network is a targetable vulnerability of mantle cell lymphomas.The Journal of clinical investigation · 2022Article
- SOX2 Promotes Invasion in Human Bladder Cancers through MMP2 Upregulation and FOXO1 Downregulation.International journal of molecular sciences · 2022Article
- Profile of chimeric RNAs and TMPRSS2-ERG e2e4 isoform in neuroendocrine prostate cancer.Cell & bioscience · 2022Article
- Targeted regulation of FoxO1 in chondrocytes prevents age-related osteoarthritis via autophagy mechanism.Journal of cellular and molecular medicine · 2022Review
- Review
- Overcoming Drug Resistance in Advanced Prostate Cancer by Drug Repurposing.Medical sciences (Basel, Switzerland) · 2022Review
- 3-Aminophthalic acid, a new cereblon ligand for targeted protein degradation by O'PROTAC.Chemical communications (Cambridge, England) · 2022Article
- A Review of Special Considerations on Insulin Resistance Induced Hyperandrogenemia in Women with Polycystic Ovary Syndrome: A Prominent COVID-19 Risk Factor.International journal of molecular and cellular medicine · 2022Article
- cDNA-detector: detection and removal of cDNA contamination in DNA sequencing libraries.BMC bioinformatics · 2021Article
- Ras/ERK and PI3K/AKT signaling differentially regulate oncogenic ERG mediated transcription in prostate cells.PLoS genetics · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 1 institution in 1 country.
Yinhui YangDepartment of Urology, the Fourth Hospital of Harbin Medical University, Harbin, Heilongjiang, China.
Alexandra M BleeDepartment of Biochemistry and Molecular Biology, Mayo Clinic College of Medicine, Rochester, Minnesota.
Dejie WangDepartment of Biochemistry and Molecular Biology, Mayo Clinic College of Medicine, Rochester, Minnesota.
Jian AnDepartment of Biochemistry and Molecular Biology, Mayo Clinic College of Medicine, Rochester, Minnesota.
Yunqian PanDepartment of Biochemistry and Molecular Biology, Mayo Clinic College of Medicine, Rochester, Minnesota.
Yuqian YanDepartment of Biochemistry and Molecular Biology, Mayo Clinic College of Medicine, Rochester, Minnesota.
Tao MaDepartment of Biochemistry and Molecular Biology, Mayo Clinic College of Medicine, Rochester, Minnesota.
Yundong HeDepartment of Biochemistry and Molecular Biology, Mayo Clinic College of Medicine, Rochester, Minnesota.
Joseph DugdaleDepartment of Biochemistry and Molecular Biology, Mayo Clinic College of Medicine, Rochester, Minnesota.
Xiaonan HouDepartment of Oncology, Mayo Clinic College of Medicine, Rochester, Minnesota.
Jun ZhangDepartment of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, Minnesota.
S John WerohaDepartment of Oncology, Mayo Clinic College of Medicine, Rochester, Minnesota.
Wei-Guo ZhuDepartment of Biochemistry and Molecular Biology, Shenzhen University School of Medicine, Shenzhen, China.
Y Alan WangDepartment of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Ronald A DePinhoDepartment of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Wanhai XuDepartment of Urology, the Fourth Hospital of Harbin Medical University, Harbin, Heilongjiang, China. huang.haojie@mayo.edu xuwanhai@163.com.
Haojie HuangDepartment of Biochemistry and Molecular Biology, Mayo Clinic College of Medicine, Rochester, Minnesota. huang.haojie@mayo.edu xuwanhai@163.com.
Mayo Clinic · US
Funding
Role of proinflammatory cytokine-induced AR degradation in castration-resistant prostate cancerR01CA130908 · NCI · STATE UNIVERSITY NEW YORK STONY BROOK · PI HUANG, HAOJIE · 2010 to 2021
$3.5MRole of FOXO1 Inactivation in Prostate TumorigenesisR01CA134514 · NCI · UNIVERSITY OF MINNESOTA · PI HUANG, HAOJIE · 2009 to 2019
$3.3MRole of RUNX2 in prostate cancer intratumoral androgen synthesis and progressionR01CA193239 · NCI · MAYO CLINIC ROCHESTER · PI HUANG, HAOJIE · 2015 to 2019
$1.8MNCI NIH HHS R01 CA130908NCI NIH HHS R01 CA134514NCI NIH HHS R01 CA193239
Abstract
E26 transformation-specific transcription factor ERG is aberrantly overexpressed in approximately 50% of all human prostate cancer due to
Indexed as
AnimalsCell Line, TumorCell ProliferationCell Transformation, NeoplasticForkhead Box Protein O1HumansMaleMiceMice, TransgenicNeoplasm InvasivenessProstateProstatic Intraepithelial NeoplasiaProstatic NeoplasmsRNA InterferenceRNA, Small InterferingSerine EndopeptidasesERG protein, humanForkhead Box Protein O1FOXO1 protein, humanRNA, Small InterferingSerine EndopeptidasesTMPRSS2 protein, humanTranscriptional Regulator ERG
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.